SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel ($INTC) is trending following a Q3 earnings beat, with much discussion around revenue growth and AI prospects. Community members are weighing profit-taking strategies against potential upside from new partnerships and government support. Bullish sentiment is fueled by the possibility of Intel regaining market share and the potential for a short squeeze.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to community discussion around its high short interest and potential for a squeeze, further fueled by NVIDIA's investment and a presentation at the GITEX Global conference in Dubai. Some anticipate news or catalysts that could trigger a significant upward move. Bullish sentiment also stems from potential expansion in the Middle East and the broader AI-driven healthcare narrative.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as Q3 sales numbers have been released, showing an overall increase driven by trucks and SUVs. Community members are discussing whether this sales momentum can continue, especially with the EV tax credit expiring and the impact of recent supplier issues. Many are also closely watching for a potential Trump-era tariff relief, which could significantly benefit Ford's bottom line.

Above Food Ingredients, Inc. engages in operating its subsidiaries, Bite Acquisition Corp. (Bite) and Above Food Corp. (Above Food). The Bite is a blank check company that affects a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Above Food is an ingredient company that provides food products and brands. The company was founded by Lionel Kambeitz on April 18, 2023 and is headquartered in Regina, Canada.

Above Food Ingredients Inc.

ABVE is trending due to anticipation surrounding its merger with Palm Global and potential access to significant gold-backed assets, with the community closely watching for news and updates on the deal's progress. Traders are actively discussing potential short squeezes and the impact of upcoming financial audits and partnership announcements. Overall sentiment suggests a mix of excitement and impatience as investors await further catalysts.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers is trending as analysts are updating ratings and price targets, influencing investor sentiment. Community members are actively discussing potential catalysts, tariff impacts, and the strength of the Hoka and UGG brands. The stock's recent volatility and oversold conditions are also fueling discussions around swing trading opportunities and long-term recovery.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

The crypto, BALLIN, is gaining attention, particularly within the Phantom Wallet community, with many touting its potential for significant gains. Community members emphasize a "winners" and "high roller" culture, promoting it as a lifestyle choice. However, some users are also reporting concerns about potential scams.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

Inhibrx Inc

Inhibrx (INBX) is trending due to positive trial results for their drug Ozekibart in treating chondrosarcoma, a rare bone cancer, leading to significant pre-market gains. The community is discussing the potential for a "PRAX-move," referencing another stock that experienced a substantial surge, while also considering potential cash offerings. Some traders are eyeing high price targets, viewing INBX as a first-mover in a market with currently no approved systemic treatment options for the disease.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending amid community discussions about potential catalysts like upcoming presentations and a possible buyout. Speculation is high, with some traders suggesting a deal could be announced before year-end due to insider activity and retention bonuses. Community members are actively debating the impact of short positions and encouraging shareholders to hold strong.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF ($BTC) is trending as Bitcoin flirts with all-time highs, fueling community excitement about potential gains. The ETF's movements are closely tied to Bitcoin's price, with discussions focusing on key support and resistance levels. Some investors are also weighing $BTC against other assets like gold and AI-related stocks.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

LUMN is trending following news of a strategic partnership with Palantir to enhance enterprise AI adoption, combining Lumen's networking capabilities with Palantir's AI platform. Community discussions revolve around the potential for top-line growth, debt reduction, and LUMN's strategic pivot into next-generation AI technology infrastructure, with some bullish investors anticipating a significant rise in share price. The move aligns with the growing demand for AI infrastructure and data connectivity, potentially positioning LUMN as a key player in the evolving AI landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm 

VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.

Veru: Discussions on tariffs are negotiation means to an end

Dan Veru, CIO at Palisade Capital, says tariffs are negotiation tools, with companies adapting, though lower-margin businesses feel the strain despite a strong dollar...

Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline

Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline...

Veru: With the new administration, the Fed may pause to see how policies will impact inflation

Veru: With the new administration, the Fed may pause to see how policies will impact inflation...

Veru: The biggest risk for the markets is to focus on just one data point

Veru: The biggest risk for the markets is to focus on just one data point...

Critical Insights From Veru Analyst Ratings: What You Need To Know

Latest Ratings for VERU
 DateFirmActionFromTo Apr 2021JefferiesInitiates Coverage OnBuy Feb 2021HC Wainwright & Co.MaintainsBuy Feb 2021HC Wainwright & Co.MaintainsBuy
 View More Analyst Ratings...

Veru Announces Date of 2024 Annual Meeting of Shareholders

--2023 Form 10-K/A and Q1 2024 Form 10-Q filed today-- --2024 Annual Meeting of Shareholders will be June 18, 2024 -- MIAMI, FL, April 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a...

Veru (NASDAQ:VERU) Coverage Initiated at Raymond James

Raymond James started coverage on shares of Veru (NASDAQ:VERU - Free Report) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The brokerage issued an outperform...

Financial Survey: Sophiris Bio (OTCMKTS:SPHS) vs. Veru (NASDAQ:VERU)

Sophiris Bio (OTCMKTS:SPHS  Get Free Report) and Veru (NASDAQ:VERU  Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two...

Veru Reschedules Annual Meeting of Shareholders

--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22...

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

VERU
Veru Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VERU News

VERUVeru Inc